ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
1-Year Return
169.78%
This Quarter Return
+46.68%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$363M
AUM Growth
+$22.8M
(+6.7%)
Cap. Flow
-$33.2M
Cap. Flow
% of AUM
-9.14%
Top 10 Holdings %
Top 10 Hldgs %
48.6%
Holding
60
New
16
Increased
14
Reduced
15
Closed
8
Top Buys
| 1 |
VistaGen Therapeutics
VTGN
|
+$14.6M |
| 2 |
BLSA
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
|
+$9.39M |
| 3 |
Replimune Group
REPL
|
+$7.92M |
| 4 |
JYAC
Jiya Acquisition Corp. Class A Common Stock
JYAC
|
+$5.79M |
| 5 |
Stoke Therapeutics
STOK
|
+$5.73M |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$43.5M |
| 2 |
Kura Oncology
KURA
|
+$11M |
| 3 |
Aldeyra Therapeutics
ALDX
|
+$9.98M |
| 4 |
Cytokinetics
CYTK
|
+$7.74M |
| 5 |
LSACU
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
|
+$7.62M |
Sector Composition
| 1 | Healthcare | 90.62% |
| 2 | Financials | 4.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
BioCryst Pharmaceuticals
BCRX
$1.67B
| – | – |
-660,000
| Closed | -$2.27M |
|
52
Cogent Biosciences
COGT
$1.78B
| – | – |
-102,500
| Closed | -$959K |
|
53
Cardiff Oncology
CRDF
$140M
| – | – |
-305,900
| Closed | -$4.34M |
|
|
54
Cytokinetics
CYTK
$6.06B
| – | – |
-357,500
| Closed | -$7.74M |
|
55
Cartesian Therapeutics
RNAC
$260M
| – | – |
-78,807
| Closed | -$5.86M |
|
56
SPDR S&P Biotech ETF
XBI
$5.42B
| – | – |
0
| – | – |
|
|
PANA.U
57
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
| – | – |
-280,000
| Closed | -$3.36M |
|
|
LSACU
58
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
| – | – |
-560,000
| Closed | -$7.62M |
|
|
IMMU
59
DELISTED
Immunomedics Inc
IMMU
| – | – |
-511,500
| Closed | -$43.5M |
|
|
BHVN
60
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| – | – |
0
| – | – |
|